Sirona Biochem Appoints David Moore to Board of Directors

Sirona Biochem Appoints David Moore to Board of Directors 
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 01/23/14 -- Sirona
Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) announced today the
appointment of David Moore to its Board of Directors.  
"We are very fortunate to have David Moore join us," said Neil
Belenkie, Chief Executive Officer of Sirona Biochem. "David's
previous experience and success in the USA leading many of the tasks
that we are about to undertake, are unique and invaluable resources
to Sirona's leadership team. With David on board, we gain another
level of confidence in our ability to execute our strategy." 
About David Moore 
David joins the board of directors with significant biotech and big
pharma experience. David is currently Chief Commercial Officer of
Cempra, a clinical-stage pharmaceutical company focused on developing
antibacterials to meet critical medical needs. Prior to joining
Cempra, David was Chief Business Officer of Ocera Therapeutics, a
publicly traded clinical stage biotech focused in advanced liver
disease. Prior to Ocera, he was Chief Business Officer of Tranzyme
Pharma, a publicly traded clinical stage biotech and macrocyclic
discovery chemistry company which David and the management team
successfully merged with Ocera Therapeutics in July 2013. David has
participated in several rounds of corporate financing, successfully
negotiated multiple license deals for both clinical stage products
and pre-clinical compounds in addition to the recent strategic merger
process. David has an extensive commercial background having spent
over 15 years developing and managing pharmaceutical commercial
programs with the majority of that time spent with Ortho-McNeil and
Janssen divisions of Johnson & Johnson. David received his B.Sc. in
Biology from Towson University and an M.B.A. from Lehigh University,
and a second graduate degree in Health Policy Excellence from Thomas
Jefferson University. 
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.  
Sirona Biochem cautions you that statements included in this press
release that are not a description of historical facts may be
forward-looking statements. 
Sirona Biochem Corp.
Christopher Hopton
Press spacebar to pause and continue. Press esc to stop.